Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

Diabetes, Obesity and Metabolism

Volumn 11, Issue 12, 2009, Pages 1122-1130

  Brixner, D I ^a   McAdam Marx, C ^a   Ye, X ^a   Boye, K S ^b   Nielsen, L ^c   Wintle, M ^c   Misurski, D ^b   Fabunmi, R ^b  

^a UNIVERSITY OF UTAH   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Blood pressure; Body mass index; Haemoglobin A1C; Type 2 diabetes; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; EXENDIN 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AMBULATORY CARE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 70450203583     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01081.x     Document Type: Article

References (26)

1. Standards of medical care in diabetes -2008. Diabetes Care 2008, 31:S12-S54. American Diabetes Association
2. Stratton IM, Adler AI, Neil HAW. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group
4. Ryan DH, Espeland MA, Foster GD. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003, 24:610-628.
5. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the Look AHEAD trial. Diabetes Care 2007, 30:1374-1383. The Look Ahead Research Group
6. Nielsen L, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008, 2:255-260.
7. Stonehouse A, Maggs D. Emerging therapies for type 2 diabetes. Curr Drug Ther 2007, 2:151-160.
8. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
9. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
10. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
11. Blonde L, Klein EJ, Han J. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
12. Ratner RE, Maggs D, Nielsen LL. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
13. Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
14. Population Estimates US Census Bureau, Washington, DC
15. Oderda G, Lieberman M, Asche C, Brixner D. Use of electronic medical record (EMR) data in outcomes research. Value Health 2007, 10:A450-A451.
16. Byetta (exenatide injection) prescribing information 2008, Amylin Pharmaceuticals Inc, Eli Lilly and Company, San Diego, CA
17. Barnett AH, Burger J, Johns D. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
18. Data on File. 2009, Amylin Pharmaceuticals Inc, AMIGO trial,
19. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
20. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005, 118(Suppl. 5A):27S-34S.
21. Drucker DJ, Buse JB, Taylor K. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet 2008, 372:1240-1250.
22. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta- analysis. Am J Clin Nutr 1992, 56:320-328.
23. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
24. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002, 26(Suppl. 4):S25-S28.
25. Palmer JL, Goodall G, Nielsen S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin 2008, 24:1417-1428.
26. Orrico KB. Sources and types of discrepancies between electronic medical records and actual outpatient medication use. J Manag Care Pharm 2008, 14:626-631.